Drugs / Cu-64 Rituximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01598558 | Jan 2012 → Dec 2015 | non-Hodgkin lymphoma | Sanjiv Sam Gambhir | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cu-64 Rituximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01598558 ↗ |
| Known as | Rituxan | “a) Phase I testing in lymphoma patients of Cu-64 labelled Rituxan for defining normal tracer biodistribution, stability, pharmacokinetics and radiation dosimetry;” NCT01598558 ↗ |
| Modality | Monoclonal antibody | “Rituximab is an antibody targeted against the CD20 antigen” NCT01598558 ↗ |
| Route | Intravenous | “Up to 14 mCi, iv” NCT01598558 ↗ |